Akero Therapeutics

AKRO50

High Growth

$29.760.00%$0.00

High Growth

AKRO50

$29.76

0.00%$0.00

High Growth

Performance History

Key Stats
Open	$32.58
Prev. Close	$32.38
EPS	-3.78
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	30.68	33.40
52 Week Range	11.25	50.29

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-3.78

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Akero Therapeutics (AKRO)

Akero Therapeutics Inc (AKRO) is a biotechnology company that focuses on the development and commercialization of innovative therapeutics for the treatment of metabolic diseases and non-alcoholic steatohepatitis (NASH). The company's lead product candidate, AKR-001, is a long-acting fibroblast growth factor 21 (FGF21) analog that has shown promising results in clinical trials. AKR-001 has the potential to address the underlying causes of NASH and other metabolic diseases by targeting multiple pathways involved in the disease process.

The stock price history of Akero Therapeutics Inc (AKRO) has seen significant fluctuations since its initial public offering (IPO) in June 2019. The stock initially had a strong performance, reaching a high of $47.22 per share in January 2020. However, the stock has since experienced a decline and is currently trading at around $20 per share. This volatility can be attributed to various factors such as clinical trial results, regulatory developments, and market conditions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Andrew Cheng M.D., Ph.D.
Headquarters: South San Francisco
Employees: 44
Exchange: NASDAQ

Keep an eye on Akero Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Akero Therapeutics 's (AKRO) price per share?

The current price per share for Akero Therapeutics (AKRO) is $29.76. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Akero Therapeutics (AKRO)?

For Akero Therapeutics (AKRO), the 52-week high is $50.3, which is 69% from the current price. The 52-week low is $11.25, the current price is 164.53% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Akero Therapeutics (AKRO) a growth stock?

Akero Therapeutics (AKRO) has shown an average price growth of -3.55% over the past three years. It has received a score of 84 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Akero Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Akero Therapeutics (AKRO) stock price performance year to date (YTD)?

As of the latest data, Akero Therapeutics (AKRO) has a year-to-date price change of 26.75%. Over the past month, the stock has experienced a price change of -0.83%. Over the last three months, the change has been 25.25%. Over the past six months, the figure is 46.6%. Looking at a longer horizon, the five-year price change stands at 49.02%.

help

Is Akero Therapeutics (AKRO) a profitable company?

Akero Therapeutics (AKRO) has a net income of -$151.76M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$172.87M. Furthermore, the EBITDA is -$269.27M.

help

What is the market capitalization of Akero Therapeutics (AKRO)?

Akero Therapeutics (AKRO) has a market capitalization of $2.08B. The average daily trading volume is 0, indicating the stock's liquidity and investor engagement.